Priliximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Priliximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease[1] and multiple sclerosis[2][3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

References[edit]

  1. ^ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. PMC 1027080Freely accessible. PMID 9135519. doi:10.1136/gut.40.3.320. 
  2. ^ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. PMID 9109860. doi:10.1212/wnl.48.4.810. 
  3. ^ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. PMID 9270561. doi:10.1212/wnl.49.2.351.